Bicycle therapeutics announces publication of article in bioconjugate chemistry, describing an extension of its proprietary technology platform based on bicyclic peptides

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting data using tris-gold complexes to increase the chemical diversity of bicycles, was published in bioconjugate chemistry. the article, titled “gold-mediated multiple cysteine arylation for the construction of highly constr
BCYC Ratings Summary
BCYC Quant Ranking